Ann Woolfrey, MD

Associate Member
Clinical Research Division
Professor, Pediatrics
University of Washington
Director, Unrelated Donor Program
Seattle Cancer Care Alliance

Education:

University of Minnesota,   1984, MD
Saint Olaf College, 1979, BA

Research Focus:

Hematopoietic cell transplant (HCT) is the only curative therapy for many life-threatening hematologic diseases, and theoretically could cure other chronic hematologic and immunologic disorders. The research projects under Dr. Woolfrey’s direction are aimed toward improving the effectiveness of hematopoietic cell transplants, particularly for patients with nonmalignant disorders. These studies explore the use of reduced intensity conditioning regimens to reduce the short and long term toxicities associated with HCT, the use of HCT to restore normal immunity in patients with HIV or refractory autoimmune diseases, and the use of alternative donors, including unrelated and mismatched related donors. Several studies will be opened this year, focused on transplant of gene modified cells to treat HIV or genetic diseases.

Clinical Expertise:

  • Optimal donor selection- unrelated marrow or PBSC donors; cord blood unit
  • Hematopoietic cell transplant for treatment of nonmalignant diseases, such as aplastic anemia, autoimmune diseases, bone marrow failure syndromes, HIV, immune deficiency, MDS, PNH.
  • Hematopoietic cell transplant for treatment of hematologic malignancies, specifically in pediatric and young adults.

Current Studies:

Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil

Allogeneic Marrow Transplantation From HLA-Identical Related Donors for Treatment of Homozygous Thalassemia Major, Sickle Cell Anemia, Congenital Pure Red Cell Aplasia (Diamond-Blackfan Anemia, DBA), and Paroxysmal Nocturnal Hemoglobinuria, and From HLA-Identical Unrelated Donors for Treatment of Paroxysmal Nocturnal Hemoglobinuria.

AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)

AMC Protocol #085: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)

A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors

Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBU’s) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

Protocol for a Research Sample Repository for Allogeneic Hemtopoietic Stem Cell Transplantation



Ann Woolfrey, MD

Contact Information

Phone
(206) 667-4453
Fax
(206) 667-4937
Email
Additional contact

Mail Stop: D3-390